Host T cells participate in the therapeutic response to NST, DLI, and autologous tumor cell vaccines.

(A) Groups of 10 C.B17-scid (▾, ●) or BALB/c mice (▿, ○) received 10⁴ 4T1 cells subcutaneously on day 0 followed by surgery on day 13 (▾, ▿), or surgery on day 13 plus NST, DLI, and autologous tumor cell vaccine (●, ○), as schematized in Figure 1A. (B) Comparison of NST to myeloablative alloSCT. Two groups of 10 BALB/c mice each received 10⁴ 4T1 cells subcutaneously on day 0, surgery on day 13, 10⁷ B10.D2 bone marrow cells intravenously on day 14, 2 × 10⁷ B10.D2 spleen cells intravenously on day 28, and autologous tumor cell vaccine on day 31. Conditioning for alloSCT consisted of 200 cGy TBI (●) or 850 cGy TBI (○) on day 13 and Cy 200 mg/kg intraperitoneally on day 17. Tumor-free survival is plotted as a function of day after tumor inoculation.